397 related articles for article (PubMed ID: 30983433)
21. Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets.
di Meo NA; Lasorsa F; Rutigliano M; Loizzo D; Ferro M; Stella A; Bizzoca C; Vincenti L; Pandolfo SD; Autorino R; Crocetto F; Montanari E; Spilotros M; Battaglia M; Ditonno P; Lucarelli G
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430837
[TBL] [Abstract][Full Text] [Related]
22. Metabolomics in renal cell carcinoma: From biomarker identification to pathomechanism insights.
Chen YY; Hu HH; Wang YN; Liu JR; Liu HJ; Liu JL; Zhao YY
Arch Biochem Biophys; 2020 Nov; 695():108623. PubMed ID: 33039388
[TBL] [Abstract][Full Text] [Related]
23. The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma.
Ambrosetti D; Dufies M; Dadone B; Durand M; Borchiellini D; Amiel J; Pouyssegur J; Rioux-Leclercq N; Pages G; Burel-Vandenbos F; Mazure NM
PLoS One; 2018; 13(2):e0193477. PubMed ID: 29481555
[TBL] [Abstract][Full Text] [Related]
24. Metabolomic profile of glycolysis and the pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma.
Lucarelli G; Galleggiante V; Rutigliano M; Sanguedolce F; Cagiano S; Bufo P; Lastilla G; Maiorano E; Ribatti D; Giglio A; Serino G; Vavallo A; Bettocchi C; Selvaggi FP; Battaglia M; Ditonno P
Oncotarget; 2015 May; 6(15):13371-86. PubMed ID: 25945836
[TBL] [Abstract][Full Text] [Related]
25. Analyses of the transcriptome and metabolome demonstrate that HIF1α mediates altered tumor metabolism in clear cell renal cell carcinoma.
Minton DR; Fu L; Chen Q; Robinson BD; Gross SS; Nanus DM; Gudas LJ
PLoS One; 2015; 10(4):e0120649. PubMed ID: 25830305
[TBL] [Abstract][Full Text] [Related]
26. RAC2 acts as a prognostic biomarker and promotes the progression of clear cell renal cell carcinoma.
Liu Y; Cheng G; Song Z; Xu T; Ruan H; Cao Q; Wang K; Bao L; Liu J; Zhou L; Liu D; Yang H; Chen K; Zhang X
Int J Oncol; 2019 Sep; 55(3):645-656. PubMed ID: 31364727
[TBL] [Abstract][Full Text] [Related]
27. Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinoma.
Schrödter S; Braun M; Syring I; Klümper N; Deng M; Schmidt D; Perner S; Müller SC; Ellinger J
Mol Cancer; 2016 Feb; 15():10. PubMed ID: 26831905
[TBL] [Abstract][Full Text] [Related]
28. The platelet isoform of phosphofructokinase contributes to metabolic reprogramming and maintains cell proliferation in clear cell renal cell carcinoma.
Wang J; Zhang P; Zhong J; Tan M; Ge J; Tao L; Li Y; Zhu Y; Wu L; Qiu J; Tong X
Oncotarget; 2016 May; 7(19):27142-57. PubMed ID: 27049827
[TBL] [Abstract][Full Text] [Related]
29. The biological roles and clinical implications of microRNAs in clear cell renal cell carcinoma.
He YH; Chen C; Shi Z
J Cell Physiol; 2018 Jun; 233(6):4458-4465. PubMed ID: 29215721
[TBL] [Abstract][Full Text] [Related]
30. Role of NADH Dehydrogenase (Ubiquinone) 1 Alpha Subcomplex 4-Like 2 in Clear Cell Renal Cell Carcinoma.
Minton DR; Fu L; Mongan NP; Shevchuk MM; Nanus DM; Gudas LJ
Clin Cancer Res; 2016 Jun; 22(11):2791-801. PubMed ID: 26783287
[TBL] [Abstract][Full Text] [Related]
31. Fatty acid binding protein 7 may be a marker and therapeutic targets in clear cell renal cell carcinoma.
Nagao K; Shinohara N; Smit F; de Weijert M; Jannink S; Owada Y; Mulders P; Oosterwijk E; Matsuyama H
BMC Cancer; 2018 Nov; 18(1):1114. PubMed ID: 30442117
[TBL] [Abstract][Full Text] [Related]
32. ECHS1 suppresses renal cell carcinoma development through inhibiting mTOR signaling activation.
Wang L; Qi Y; Wang X; Li L; Ma Y; Zheng J
Biomed Pharmacother; 2020 Mar; 123():109750. PubMed ID: 31891870
[TBL] [Abstract][Full Text] [Related]
33. Metabolomics studies in gastrointestinal cancer: a systematic review.
Yu J; Zhao J; Zhang M; Guo J; Liu X; Liu L
Expert Rev Gastroenterol Hepatol; 2020 Jan; 14(1):9-25. PubMed ID: 31786962
[No Abstract] [Full Text] [Related]
34. Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis.
Wettersten HI; Hakimi AA; Morin D; Bianchi C; Johnstone ME; Donohoe DR; Trott JF; Aboud OA; Stirdivant S; Neri B; Wolfert R; Stewart B; Perego R; Hsieh JJ; Weiss RH
Cancer Res; 2015 Jun; 75(12):2541-52. PubMed ID: 25952651
[TBL] [Abstract][Full Text] [Related]
35. Value of global metabolomics in association with diagnosis and clinicopathological factors of renal cell carcinoma.
Sato T; Kawasaki Y; Maekawa M; Takasaki S; Saigusa D; Ota H; Shimada S; Yamashita S; Mitsuzuka K; Yamaguchi H; Ito A; Kinoshita K; Koshiba S; Mano N; Arai Y
Int J Cancer; 2019 Jul; 145(2):484-493. PubMed ID: 30628065
[TBL] [Abstract][Full Text] [Related]
36. Role of metabolomics-derived biomarkers to identify renal cell carcinoma: a comprehensive perspective of the past ten years and advancements.
Gupta A; Nath K; Bansal N; Kumar M
Expert Rev Mol Diagn; 2020 Jan; 20(1):5-18. PubMed ID: 31825678
[No Abstract] [Full Text] [Related]
37. New strategies in renal cell carcinoma: targeting the genetic and metabolic basis of disease.
Srinivasan R; Ricketts CJ; Sourbier C; Linehan WM
Clin Cancer Res; 2015 Jan; 21(1):10-7. PubMed ID: 25564569
[TBL] [Abstract][Full Text] [Related]
38. Low level of PDZ domain containing 1 (PDZK1) predicts poor clinical outcome in patients with clear cell renal cell carcinoma.
Zheng J; Wang L; Peng Z; Yang Y; Feng D; He J
EBioMedicine; 2017 Feb; 15():62-72. PubMed ID: 27993630
[TBL] [Abstract][Full Text] [Related]
39. Identification and validation of TGFBI as a promising prognosis marker of clear cell renal cell carcinoma.
Lebdai S; Verhoest G; Parikh H; Jacquet SF; Bensalah K; Chautard D; Rioux Leclercq N; Azzouzi AR; Bigot P
Urol Oncol; 2015 Feb; 33(2):69.e11-8. PubMed ID: 25035170
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
